Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2021

01-01-2021 | Lymphoma | Original Article

The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt

Authors: Doaa Mohamed El Demerdash, Nehad Mohamed Tawfik, Raghda Elazab, Maha Hamdi El Sissy

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2021

Login to get access

Abstract

Non-Hodgkin lymphoma (NHL) is an etiologically, clinically, and histologically heterogeneous group of lymphoproliferative disorders. Immune dysfunction is a well-known risk factor and dysregulation of cytokines may mediate disease progression. Obesity is one of the important relations connecting immune system abnormalities and lymphomagenesis. We conducted a study to find out the association between obesity as measured by body mass index (BMI), and risk of non-Hodgkin lymphoma (NHL) development by assessment the of inflammatory cytokines levels, (IL-6, IL-10, IFN-gamma and CRP) and adipokines levels (leptin and adiponectin). Also, to predict the effect of higher BMI on the incidence of NHL. The study included 180 NHL patients and 172 healthy controls. The inflammatory markers (IL-6, IL-10, IFN-γ & CRP) together with adiponectin were assessed by ELISA technique. IL-6, IL-10, CRP, IFN-γ and Adiponectin were statistically higher in cases than control. A positive significant difference of Leptin (p-value 0.001) was found with higher levels in patients with BMI (≥ 25 kg/m2) than in patients with < 25 kg/m2. IL-6, IL-10, CRP, IFN-γ and Adiponectin could be implicated in lymphomagenesis in Egyptian NHL. The study results support the hypothesis that obesity has a major role in the development of NHL. An association between Leptin and NHL risk with higher levels in patients with BMI (≥ 25 kg/m2) was proved.
Literature
1.
go back to reference Ekstrom SK, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the inter lymph consortium. Blood 111:4029–4038CrossRef Ekstrom SK, Vajdic CM, Falster M et al (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the inter lymph consortium. Blood 111:4029–4038CrossRef
2.
go back to reference Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRef Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRef
3.
go back to reference Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–767CrossRef Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–767CrossRef
4.
go back to reference Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRef Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355CrossRef
5.
go back to reference De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546CrossRef De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546CrossRef
6.
go back to reference Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613CrossRef Vainchenker W, Constantinescu SN (2013) JAK/STAT signaling in hematological malignancies. Oncogene 32:2601–2613CrossRef
7.
go back to reference Gopal A, Kahl B, de Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al (2014) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Clin Adv Hematol Oncol 12:8–9 Gopal A, Kahl B, de Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al (2014) Mature response data from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Clin Adv Hematol Oncol 12:8–9
8.
go back to reference Beltowski J, Jamroz-Wisniewska A, Widomska S (2008) Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8:7–46CrossRef Beltowski J, Jamroz-Wisniewska A, Widomska S (2008) Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8:7–46CrossRef
9.
go back to reference Saxena NK, Sharma D (2010) Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 4:358–362CrossRef Saxena NK, Sharma D (2010) Metastasis suppression by adiponectin: LKB1 rises up to the challenge. Cell Adh Migr 4:358–362CrossRef
10.
go back to reference Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265–2273CrossRef Cerhan JR, Slager SL (2015) Familial predisposition and genetic risk factors for lymphoma. Blood 126:2265–2273CrossRef
11.
go back to reference Roberts D, Dive C, Renehan A (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med 61:301–316CrossRef Roberts D, Dive C, Renehan A (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Ann Rev Med 61:301–316CrossRef
12.
go back to reference Renehan AG (2011) Epidemiology of overweight/obesity and cancer risk. In: McTiernan A (ed) Physical activity, dietary calorie restriction, and cancer, vol 3. Springer, New York, pp 5–23CrossRef Renehan AG (2011) Epidemiology of overweight/obesity and cancer risk. In: McTiernan A (ed) Physical activity, dietary calorie restriction, and cancer, vol 3. Springer, New York, pp 5–23CrossRef
13.
go back to reference Conroy SM, Maskarinec G, Morimoto Y et al (2013) Non-Hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 22(3):337–347CrossRef Conroy SM, Maskarinec G, Morimoto Y et al (2013) Non-Hodgkin lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 22(3):337–347CrossRef
14.
go back to reference Hadi DA, Shani WS, Khalaf AA et al (2013) Serum levels of interleukin-6 and interleukin-10 in adult newly diagnosed Iraqi non-Hodgkin’s lymphoma patients. Euro J Exp Bio 3(5):441–446 Hadi DA, Shani WS, Khalaf AA et al (2013) Serum levels of interleukin-6 and interleukin-10 in adult newly diagnosed Iraqi non-Hodgkin’s lymphoma patients. Euro J Exp Bio 3(5):441–446
15.
go back to reference Hsu SM, Xie SS, Waldron JA (1992) Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. Am J Pathol 141(4):915–923PubMedPubMedCentral Hsu SM, Xie SS, Waldron JA (1992) Functional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas. Am J Pathol 141(4):915–923PubMedPubMedCentral
16.
go back to reference Purdue MP, Lan Q, Bagni R et al (2011) Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin Lymphoma. Cancer Res 71(14):4898–4907CrossRef Purdue MP, Lan Q, Bagni R et al (2011) Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin Lymphoma. Cancer Res 71(14):4898–4907CrossRef
17.
go back to reference Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 10(4):669–674PubMed Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma. Asian Pac J Cancer Prev 10(4):669–674PubMed
18.
go back to reference Epeldegui M, Widney DP, Martinez-Maza O (2006) Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18:444–448CrossRef Epeldegui M, Widney DP, Martinez-Maza O (2006) Pathogenesis of AIDS lymphoma: role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 18:444–448CrossRef
19.
go back to reference Voorzanger N, Touitou R, Garcia E et al (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505PubMed Voorzanger N, Touitou R, Garcia E et al (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505PubMed
20.
go back to reference Chen Y, Zheng T, Lan Q et al (2011) Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 117:585–590CrossRef Chen Y, Zheng T, Lan Q et al (2011) Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood 117:585–590CrossRef
21.
go back to reference Saberi HF, Krop EJ, Scoccianti C et al (2010) Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 19:1577–1584CrossRef Saberi HF, Krop EJ, Scoccianti C et al (2010) Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 19:1577–1584CrossRef
22.
go back to reference Shivappa N, He’bert JR, Taborelli M et al (2017) Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case–control study. Cancer Causes Control 28:791–799CrossRef Shivappa N, He’bert JR, Taborelli M et al (2017) Dietary inflammatory index and non-Hodgkin lymphoma risk in an Italian case–control study. Cancer Causes Control 28:791–799CrossRef
23.
go back to reference Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the inter lymph consortium. Lancet Oncol 7(1):27–38CrossRef Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the inter lymph consortium. Lancet Oncol 7(1):27–38CrossRef
24.
go back to reference La CA, Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4:371–379CrossRef La CA, Matarese G (2004) The weight of leptin in immunity. Nat Rev Immunol 4:371–379CrossRef
25.
go back to reference Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13(5):779–786PubMed Skibola CF, Holly EA, Forrest MS et al (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13(5):779–786PubMed
26.
go back to reference Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816CrossRef Willett EV, Skibola CF, Adamson P et al (2005) Non-Hodgkin’s lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer 93:811–816CrossRef
27.
go back to reference Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594CrossRef Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594CrossRef
28.
go back to reference Petridou ET, Sergentanis TN, Dessypris N et al (2009) Serum adiponectin as a predictor of childhood non-Hodgkin’s lymphoma: a nationwide case-control study. J Clin Oncol 27:5049–5055CrossRef Petridou ET, Sergentanis TN, Dessypris N et al (2009) Serum adiponectin as a predictor of childhood non-Hodgkin’s lymphoma: a nationwide case-control study. J Clin Oncol 27:5049–5055CrossRef
29.
go back to reference Pamuk GE, Turgut B, Demir M et al (2006) Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 25:537–541PubMed Pamuk GE, Turgut B, Demir M et al (2006) Increased adiponectin level in non-Hodgkin lymphoma and its relationship with interleukin-10. Correlation with clinical features and outcome. J Exp Clin Cancer Res 25:537–541PubMed
30.
go back to reference Wei T, Ye P, Xin PX et al (2016) circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget 7(30):48671–48691CrossRef Wei T, Ye P, Xin PX et al (2016) circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies. Oncotarget 7(30):48671–48691CrossRef
31.
go back to reference Hellström L, Wahrenberg H, Hruska K et al (2000) Mechanisms behind gender difference in circulating leptin levels. J Intern Med 247:457–462CrossRef Hellström L, Wahrenberg H, Hruska K et al (2000) Mechanisms behind gender difference in circulating leptin levels. J Intern Med 247:457–462CrossRef
32.
go back to reference Kelly JL, Fredericksen ZS, Liebow M et al (2012) The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol 22:855–862CrossRef Kelly JL, Fredericksen ZS, Liebow M et al (2012) The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol 22:855–862CrossRef
33.
go back to reference Patel AV, Diver WR, Teras LR et al (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54(6):1221–1227CrossRef Patel AV, Diver WR, Teras LR et al (2013) Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Leuk Lymphoma 54(6):1221–1227CrossRef
34.
go back to reference Bertrand KA, Giovannucci E, Zhang SM et al (2013) A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res 6(8):864–873CrossRef Bertrand KA, Giovannucci E, Zhang SM et al (2013) A prospective analysis of body size during childhood, adolescence, and adulthood and risk of non-Hodgkin lymphoma. Cancer Prev Res 6(8):864–873CrossRef
35.
go back to reference Golubovic I, Marjanovic G, RadojKovic D et al (2017) Overweight, obesity and physical activity in relation to follicular lymphoma incidence and mortality: a meta-analysis. Arch Pathol Clin Res 1:024–034 Golubovic I, Marjanovic G, RadojKovic D et al (2017) Overweight, obesity and physical activity in relation to follicular lymphoma incidence and mortality: a meta-analysis. Arch Pathol Clin Res 1:024–034
36.
go back to reference Winer DA, Winer S, Chng MH et al (2014) B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci 71:1033–1043CrossRef Winer DA, Winer S, Chng MH et al (2014) B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance. Cell Mol Life Sci 71:1033–1043CrossRef
Metadata
Title
The Association of Pre-diagnostic Inflammatory Markers and Adipokines and the Risk of Non-Hodgkin Lymphoma Development in Egypt
Authors
Doaa Mohamed El Demerdash
Nehad Mohamed Tawfik
Raghda Elazab
Maha Hamdi El Sissy
Publication date
01-01-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01305-9

Other articles of this Issue 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine